High dose intravenous immunoglobulin for the treatment of autoimmune bullous diseases.
Not Applicable
Recruiting
- Conditions
- autoimmune bullous diseases
- Registration Number
- JPRN-UMIN000012601
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
Patients of 5 years from the history of malignancy. Patients who have treated with steroid or immunosuppressant in 14 days. Patients with high-risk history of thrombosis, embolism. Patients who have treated with high dose intravenous immunoglobulin in 6 months. Patients who have history of secondary effect of blood products.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pemphigus Disease Area Index: PDAI Pemphigus Score
- Secondary Outcome Measures
Name Time Method